Gliclazide is a second-generation sulfonylurea hypoglycemic drug, the advantage is that it is suitable for some non-insulin-dependent diabetes mellitus that cannot be controlled by diet therapy alone, and it can also inhibit the occurrence of cardiovascular and cerebrovascular complications in patients with diabetes mellitus. The disadvantage is that it is forbidden for patients with type 1 diabetes, severe hepatic and renal insufficiency. It is prone to cause hypoglycemia, allergic reactions, leukopenia and other adverse reactions. Gliclazide is a pro-insulin secretion agent, oral effect, strong hypoglycemic effect, outstanding efficacy, for those patients who take sulfonylureas are not effective still have good efficacy. It can not only improve the sugar metabolism in diabetic patients, but also reduce the risk of cardiovascular and cerebrovascular complications in diabetic patients. Patients with type 1 diabetes, severe hepatic and renal insufficiency, and severe infections are prohibited. At the same time, individual patients may experience adverse reactions such as hypoglycemia, allergies and skin rashes. The use of drugs should be carried out under the guidance of a doctor, and the occurrence of adverse drug reactions should be promptly consulted to avoid the development of the disease.